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Triggers of Inflammatory Heart
Disease
Ninaad Lasrado1, Bharathi Yalaka1,2 and Jay Reddy1*
1 School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE, United States,
2 Bristol-Myers Squibb – Hopewell, Pennington, NJ, United States
Inflammatory heart disease (IHD) is a group of diseases that includes pericarditis,
myocarditis, and endocarditis. Although males appear to be more commonly affected
than females, IHD can be seen in any age group. While the disease can be self-limiting
leading to full recovery, affected individuals can develop chronic disease, suggesting
that identification of primary triggers is critical for successful therapies. Adding to this
complexity, however, is the fact that IHD can be triggered by a variety of infectious and
non-infectious causes that can also occur as secondary events to primary insults. In this
review, we discuss the immunological insights into the development of IHD as well as a
mechanistic understanding of the disease process in animal models.
Keywords: autoimmune diseases, myocarditis, pericarditis, endocarditis, microbes, inflammatory heart disease,
bacteria
INTRODUCTION
The immune system has evolved to fight infections. Upon exposure to microbial infections, the
innate immune cells swiftly come to the body’s defense, and, as infections get established, cells
of the adaptive immune system respond to prevent future recurrences. Nevertheless, the immune
system is not expected to recognize self-tissues as foreign. Should such misdirected responses occur,
the autoimmunity that ensues needs to be distinguished from auto inflammatory diseases. However,
both are marked by dysregulated and chronic activation of the immune system against self-antigens
in the genetically predisposed individuals.
Autoimmunity can occur in any healthy individuals as evidenced by the detection of low levels
of autoantibodies (Waldner, 2009; Lleo et al., 2010). Thus, autoimmunity and autoimmune disease
should be distinguished clinically in that autoimmune disease occurs only when autoimmunity
leads to tissue damage disrupting the functions of affected organs. The National Institutes of
Health estimates that approximately 23 million people (up to 8% of the total population) could
be affected by some form of approximately 80 known autoimmune diseases (Selgrade et al., 1999).
In fact, autoimmune disease represents the fourth largest cause of disability among women in
the United States, and is the eighth leading cause of death in women between the ages of 15
Abbreviations: AHA, anti-heart antibodies; ANT, adenine nucleotide translocator; BAR, beta adrenergic receptor; BCKD,
branched chain ketoacid dehydrogenase; CMV, cytomegalovirus; cTnI, cardiac troponin I; cTnT, cardiac troponin T; CVB,
Coxsackievirus B; DCM, dilated cardiomyopathy; DTH, delayed-type hypersensitivity; EBV, Epstein-Barr virus; GPI, glycosyl
phosphatidyl inositol; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSPs, heat shock proteins; IBV,
influenza B virus; IFN, interferon; IHD, inflammatory heart disease; IL, interleukin; ILCs, innate lymphoid cells; IRAP,
inflammatory recurrent acute pericarditis; mAb, monoclonal antibody; MHC, major histocompatibility complex; M. tb,
Mycobacterium tuberculosis; NK-Ts, natural killer-T cells; NLR, NOD-like receptor; PCR, polymerase chain reaction; RA,
rheumatoid arthritis; SERCA2a, sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a; SLE, systemic lupus erythematosus;
TCR, T cell receptor; Th, T helper; TNF, tumor necrosis factor.
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and 64 (Fairweather and Rose, 2004; Benros et al., 2014).
Additionally, diagnosis of autoimmune diseases may take up
to 5 years, and as many as five doctors may see a patient
before proper diagnosis is made (Cassell and Rose, 2003).
Economically, annual direct health care costs resulting from
autoimmune diseases are estimated to be $100 billion (2005).
Mechanistically, autoimmune diseases are considered to be
disorders of the adaptive immune system. While autoantibodies
mediate tissue damage via activation of complement proteins and
leukocytes, autoreactive T cells induce damage via delayed-type
hypersensitivity (DTH) reaction by secreting primarily T helper
(Th)1, (interferon-γ) and Th17 (interleukin-17 family) cytokines.
Two major factors have been implicated in the development of
autoimmune responses: genetic susceptibility and environmental
triggers such as exposure to microbes. Hypothetically, if ∼8% of
the U.S. population are affected with some form of autoimmune
disease, then it is hard to envision a scenario in which genetic
defects exist in all of those affected. Thus, both genetic and
environmental factors appear to be inseparable for occurrence of
organ-specific autoimmune diseases that also include diseases of
the cardiovascular system.
Conversely, auto inflammatory diseases involve direct
participation of cells of the innate immune system, importantly
neutrophils and macrophages. Cells of the adaptive immune
system including major histocompatibility complex (MHC)
alleles as well as infectious agents are excluded as the causative
factors of auto inflammatory diseases (McGonagle and
McDermott, 2006). These disorders could be monogenetic
(involvement of a single gene) (Drenth et al., 1999) or
polygenetic (involvement of more than one gene) (Doria
et al., 2012). For example, mutations in inflammasome-related
proteins, particularly NOD-like receptor (NLR) genes, are
commonly implicated in auto inflammatory disorders with
a phenotype of recurrent inflammation and periodic fever
attacks (Zhong et al., 2016). Nevertheless, auto inflammatory
diseases can affect the cardiovascular system with a phenotype
of myocarditis, pericarditis/inflammatory recurrent acute
pericarditis (IRAP), as might occur in sarcoidosis and
eosinophilic granulomatosis associated polyangiitis (Dennert
et al., 2010a; Bocoum et al., 2011).
In this review, we discuss the mechanistic insights into the
development of inflammatory heart disease (IHD), a group of
disorders that affect different layers of the heart (Figure 1). These
include pericarditis (inflammation of the outer membranous sac),
myocarditis (inflammation of the heart muscle), and endocarditis
(inflammation of the inner lining of the heart and heart
valves and/or coronary arteries) (Fairweather and Rose, 2005;
Lu et al., 2015).
Pericarditis
The pericardium is made up of an outer single-layered fibrous
membranous sac, and an inner double-layered serous sac that
covers the heart and great blood vessels. Pericarditis, although
self-limiting, can be complicated by pericardial effusion or
pericardial constriction (Troughton et al., 2004). While, 40–
85% of patients affected with pericarditis may have unknown
etiologies, recurrences can occur in up to 20–50% of those
affected (Brucato et al., 2008; Fancello et al., 2014). Acute
pericarditis can be seen in all age groups, but males are
more commonly affected than females in the age group of
20–50 years (Ariyarajah and Spodick, 2007). Estimates indicate
that 0.1% of people admitted to hospitals with chest pain can
have pericarditis (Imazio and Trinchero, 2007). Similarly, 5%
of those admitted with chest pain in emergencies unrelated
to myocardial infarction might have pericarditis (Imazio et al.,
2010; LeWinter, 2014). The disease is self-limiting in most
patients (70–90%) and respond well to anti-inflammatory
medications like aspirin or non-steroidal anti-inflammatory
drugs with colchicine, corticosteroids, and anakinra (IL-1
receptor antagonist) (Imazio et al., 2010). A variety of
infectious and non-infectious triggers have been implicated in
the causation of pericarditis (Table 1). Microbes frequently
associated with pericarditis include bacteria [Staphylococcus
aureus, Streptococcus, Haemophilus, Coxiella burnetti, and
Mycobacterium tuberculosis (M. tb)] (Pankuweit et al., 2005;
Brucato et al., 2008), viruses [Echovirus, Coxsackievirus B
(CVB), parvovirus B19, human herpes virus 6 (HHV6), Epstein-
Barr Virus (EBV), human immunodeficiency virus (HIV), and
influenza B virus (IBV)] (Brucato et al., 2008). The disease can
also arise from co-infections caused by multiple organisms such
as S. aureus and M. tb in immune-suppressive individuals as
might occur in HIV infection imposing a clinical challenge to
target specific pathogens for therapy particularly in patients with
recurrences (Lamas et al., 2019).
The most alarming complication of acute pericarditis is IRAP,
which occurs in 15–30% of patients due to auto inflammatory
or autoimmune events (Lazaros et al., 2017). Auto inflammatory
reactions in IRAP can result from virus infections such as
Echovirus, CVB, and bacteria like M. tb, but the affected
individuals should be negative for microbe-specific RNA and
antibodies (IgM) to qualify for IRAP-diagnosis (Imazio et al.,
2010; Bogdanos et al., 2013; LeWinter, 2014). However, the IRAP
patients can carry anti-heart (AHA: myosin heavy chain β and
β and myosin light chain-1v isoform) and anti-intercalated-
disk autoantibodies, in addition to non-cardiac autoantibodies
(Maisch et al., 1991; Latif et al., 1993). Impaired function
of the innate immune system resulting in auto inflammatory
pericarditis can occur due to mutations in immune response
genes. Two such examples include mutations in MEFV and
TNFRSF1A that cause Mediterranean fever and TNF receptor-
associated periodic syndrome, respectively (Cantarini et al., 2010;
Maggiolini et al., 2011).
As for autoimmune pericarditis, involvement of the
pericardium has been reported in systemic autoimmune diseases
such as systemic lupus erythematosus (SLE), rheumatoid arthritis
(RA), progressive systemic sclerosis, Sjögrens syndrome, and
polyarthritis, but the affected patients can remain asymptomatic
(Cantarini et al., 2015). Pericardial fluid, and not plasma
samples, may contain inflammatory mediators like IL-6, IL-8,
and IFN-γ with a preferential detection of anti-myolemma over
anti-sarcolemma antibodies, implying that local autoimmune
events can occur specific to the heart (Pankuweit et al., 2000).
Recent reports indicate that serum carcinoembryonic antigen cell
adhesion molecule 1 and MHC class I chain-related protein A
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FIGURE 1 | Proposed mechanisms of inflammatory heart disease. All three layers (pericardium, myocardium, and endocardium) individually or together can be
affected by various infectious and non-infectious causes. A variety of innate immune cells like neutrophils, macrophages, dendritic cells including γδ T cells, ILCs,
and NK-T cells can infiltrate and take part in tissue destruction. The inflammatory damage can also lead to the release of cardiac antigens such as cardiac myosin,
actin, cTnI, ANT, BAR, BCKD, SERCA2a, laminin, muscarinic receptor (MR), and heat shock proteins (HSP). The newly released antigens can trigger autoimmune
responses by activating T cells and B cells in the draining lymph nodes, which can in turn infiltrate the heart and aggravate inflammation. It is also possible that the
dying cardiac myocytes can be engulfed by macrophages as a part of the cleaning process by phagocytosis, and possibly, autophagy, and trigger pathogenic
autoimmune responses in genetically susceptible individuals. Alternatively, misfolded or mutated or modified self-proteins as might occur with mitochondrial proteins
can be seen by the immune system as foreign, resulting in pathological autoimmune responses. It also is possible that some of the intracellular proteins like HSPs
may bear sequences similar to microbial HSPs leading to the generation of cross-reactive immune responses. In all these scenarios, self-antigens can be presented
to both CD4 and CD8 T cells, and B cells. They mediate inflammation through, respectively, DTH, cytolysis and complement activation. However, it is to be noted
that several putative cardiac antigens can be promiscuously expressed in non-cardiac tissues such as brain, lungs, liver, pancreas, kidney, and skeletal muscle,
raising the question whether autoreactive responses generated in response to cardiac damage can also inflict damage in other organs.
can be used as biomarkers and prognostic markers in pericarditis
patients, respectively, whereas the appearance of cardiac
troponin-T (cTnT) signifies occurrence of acute and recurrent
pericarditis (Hamm et al., 1997; Gamaza-Chulián et al., 2014).
Myocarditis
Myocarditis may involve cardiac myocytes, interstitial, or
vascular elements of the heart that can be manifested as
perimyocarditis involving the pericardium. Affected patients
may show clinical manifestations of disease or may remain
asymptomatic, but histopathologic changes can be detected
in those affected (Fabre and Sheppard, 2006). Myocarditic
hearts can contain variable numbers of lymphocytes and
macrophages, but antibody-mediated injury also can be expected
(Cooper, 2009; Schultz et al., 2009). The disease is generally
regarded as an underdiagnosed cause of acute heart failure, and
sudden death or dilated cardiomyopathy (DCM) can be expected
in young adults (Drory et al., 1991). The annual global prevalence
of myocarditis has been estimated to be ∼22 cases per 100,000
patients (Drory et al., 1991; Roth et al., 2015), and 1–5% of acute
viral infections may have myocardial involvement (Fairweather
and Rose, 2005). Furthermore, myocarditis is relatively more
common in young men than their female counterparts, indicating
that sex hormones can influence the disease outcome (Kytö
et al., 2013). While virus-induced myocarditis in neonates and
children may lead to fulminant myocarditis, lymphocytic or giant
cell myocarditis is generally noted in the median age group
of 42–43 years (Rose, 2016). Approximately 10–20% of those
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TABLE 1 | Potential major causes of inflammatory heart disease.
Microbes Non-microbes
Pericarditis Viruses Systemic lupus
erythematosus
Enteroviruses (CVB and
echovirus)
Sjögrens syndrome
Herpesviruses (EBV and HHV6) Rheumatoid arthritis
Adenovirus Scleroderma
Parvovirus B19 Familial Mediterranean
fever
Influenza virus TNFR-associated periodic
syndrome
Hepatitis B and C viruses Neoplasms
Human immunodeficiency virus
Bacteria
Mycobacterium tuberculosis
Myocarditis Viruses
Enteroviruses (CVB and
echovirus)
Inflammatory bowel
disease
Erythroviruses (Parvovirus B19) Giant cell myocarditis
Adenovirus Diabetes mellitus
Human herpesvirus 6 and 7 Sarcoidosis
Hepatitis C virus Systemic lupus
erythematosus
Human immunodeficiency virus Thyrotoxicosis
Epstein-Barr virus Alcohol
Cytomegalovirus Doxorubicin
Influenza virus Hypersensitivity
Bacteria Sulphonamides
Corynebacterium diphtheriae Penicillins
Staphylococcus aureus Digoxin
Streptococcus aureus
Borrelia burgdorferi
Mycoplasma pneumoniae
Treponema pallidum
Fungus
Aspergillus species
Candida species
Coccidioides species
Cryptococcus species
Histoplasma species
Protozoa
Trypanosoma cruzi
Babesia species
Endocarditis Bacteria Intravenous drug usage
Staphylococcus aureus Rheumatoid arthritis
Streptococci species Systemic lupus
erythematosus
Enterococci species Diabetes mellitus
Haemophilus species Cancer
Aggregatibacter species Poor dental health care
Cardiobacterium species
Actinobacillus
actinomycetemcomitans
Eikenella corradens
Kingella species
(Continued)
TABLE 1 | Continued
Microbes Non-microbes
Fungus
Candida species
CVB, Coxsackie B virus; EBV, Epstein-Barr virus; HHV6, human herpesvirus 6;
TNFR, tumor necrosis factor receptor.
affected with acute myocarditis as young adults develop chronic
myocarditis, DCM, and congestive heart failure. Approximately
half of these patients undergo heart transplantation due to
the lack of effective treatment options (Caforio et al., 2010;
Rose, 2016).
Myocarditis can occur in association with a wide spectrum
of infectious agents, systemic diseases, and hypersensitivity to
drugs and toxins (Table 1). While viral infections caused by
enteroviruses like CVB, adenoviruses, parvovirus B19, CMV,
EBV, HIV, hepatitis C virus, and influenza virus are commonly
suspected as causes of myocarditis in the developed world
(Pollack et al., 2015), rheumatic carditis/diphtheria caused by
Streptococcus aureus and Chagas disease caused by Trypanosoma
cruzi are implicated in developing countries (Anez et al., 1999;
Grumbach et al., 1999; Arbustini et al., 2000; Nolte et al., 2000;
Boruah et al., 2010). More recently, it has been noted that
patients receiving checkpoint inhibitors for tumors can develop
autoimmune myocarditis, raising the question whether anti-
tumor T cells may recognize cardiac antigens by cross-reactivity
with microbial antigens (Brumbaugh et al., 2019; Martin Huertas
et al., 2019). In support of this proposition, it was recently
shown translationally that commensal bacteria can promote
inflammatory cardiomyopathy by elevating Bacteroides-specific
CD4 T cell and B cell responses in human myocarditis patients
(Gil-Cruz et al., 2019). This observation was also complemented
in the mouse model, where cardiac myosin-specific Th17
cells could be activated by cross-reactive mimic peptides from
Bacteroides thetaiotaomicron. These findings suggest that the
microbiome could predispose genetically susceptible individuals
undergoing checkpoint inhibitors to develop myocarditis, leading
to the suggestion that they can potentially be treated with
antibiotics (Gil-Cruz et al., 2019).
In North America, myocarditis/DCM has been frequently
associated with enterovirus infections like CVB, and
approximately 50% of DCM patients can carry CVB-reactive
antibodies, and viral RNA can be detected in 70% of them
(Baboonian and McKenna, 2003; Fujinami et al., 2006). However,
other viruses namely, parvovirus B19 and HHV-6 are now being
increasingly reported in association with myocarditis/DCM
(Andreoletti et al., 2009; Pollack et al., 2015). The CVB infection
is generally used to understand how viral infections can trigger
autoimmune responses. CVB pathogenesis involves both
virus-induced (direct) and host-induced (indirect) mechanisms
(Cihakova and Rose, 2008). Because it is a cardiotropic and
lytic virus, CVB can directly lyse cardiomyocytes during viral
replication. Experimentally, CVB infection in mice can have
two phases in continuum: acute myocarditis (viral) up to day
14–18 and chronic myocarditis (non-viral) beyond 18 days
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(Rose et al., 1986). During the initial stages of CVB infection,
activation of innate immune cells results in the production
of the pro-inflammatory cytokines IL-1, IL-6, TNF-β, soluble
IL-1R-like 1 also called, sST2 and IFNs (Fairweather et al., 2003;
Nishimura et al., 2018). Such proteins can potentially be used
as markers of myocarditis. For example, it has been recently
shown that men with myocarditis had higher levels of sST2 than
women. This finding was later confirmed experimentally, where
gonadectomy with testosterone, but not estradiol replacement,
led to increased levels of sST2 in male mice with myocarditis
(Coronado et al., 2019). These data also add credence to the
relevance of experimental models to human diseases. As to
adaptive immune response, Th cells appear to play a decisive
role in the induction of chronic myocarditis/DCM, but involve
complex mechanisms. While, the Th1 cells can protect acute
myocarditis and prevent viral replication (Fairweather et al.,
2004; Fairweather et al., 2005), Th2 cells, although they have
the ability to attenuate acute myocarditis via anti-inflammatory
cytokines and Treg cells (Frisancho-Kiss et al., 2007; Liu and
Huber, 2011), can induce acute cardiac remodeling leading to
chronic myocarditis/DCM (Abston et al., 2012). Conversely,
Th17 cells contribute to the development of both acute
myocarditis (but without affecting viral replication), as well as
cardiac remodeling/DCM events and heart failure (Fairweather
et al., 2012) suggesting that the disease course of viral myocarditis
may be dictated by nature and the amount of Th cytokines being
produced. Nonetheless, these findings raise a question as to the
mechanisms of generation of pathogenic cardiac-reactive T cells,
should they be antigen-specific.
One mechanism is molecular mimicry, which involves
the generation of cross-reactive immune responses against
self-antigens. In fact, sequence similarities of up to 40% have
been detected between CVB viral protein1 (VP1), streptococcal
M protein, and cardiac myosin; synthetic peptides containing
these sequences block monoclonal antibody (mAb) reactivity
to streptococcal M protein (Cunningham et al., 1992).
Furthermore, murine anti-streptococcal mAbs that cross-
react with streptococcal M protein and human cardiac myosin
were found to neutralize CVB viruses (CVB3 and CVB4) and
poliovirus type 1 (Cunningham et al., 1992). Additionally, T
lymphocytes from CVB-infected animals can respond to peptides
from streptococcal M protein (Huber et al., 1994). Similarly,
the N-terminal region four peptide from streptococcus could
induce IHD in MRL/++ mice, whereas induction of anergy
to this peptide protects mice from developing CVB-induced
myocarditis (Huber and Cunningham, 1996).
Another mechanism is epitope spreading which may occur
as a result of release of self-antigens primarily by viral
damage, leading to induction of autoimmunity secondarily
(Fujinami et al., 2006). In addressing this phenomenon, we had
demonstrated that A/J mice infected with CVB produce Myhc-
α 334-352-specific CD4 T cell responses that are pathogenic in
nature (Gangaplara et al., 2012). Using MHC class II dextramers
specific to Myhc 334–352, we showed that Myhc-specific,
CD4 T cells can infiltrate into the hearts of animals infected
with CVB during the post infectious phase of CVB infection
(Gangaplara et al., 2012). By expanding this observation, we may
be able to determine whether autoreactive T cells specific to
multiple cardiac antigens could contribute to CVB pathogenesis.
This effort, however, requires identification of myocarditogenic
epitopes for other putative cardiac antigens implicated in
myocarditis/DCM patients (Figure 1).
Endocarditis
Endocarditis can also be caused by infective or non-infective
agents (Table 1), that have a male preponderance (Aksoy et al.,
2007). Incidence of infective endocarditis in developed countries
is 3–10 cases per 100,000 people, and the disease prevalence
is expected to be high in developing countries (Duval et al.,
2012; Selton-Suty et al., 2012). Endocarditic lesions, primarily
called vegetation, consist of microorganisms, inflammatory
cells, platelets, and fibrin. Microbes such as S. aureus,
Streptococcus species, Enterococcus species, and HACEK
Gram-negative bacteria (Haemophilus species, Actinobacillus
actinomycetemcomitans, Cardiobacterium hominis, Eikenella
corrodens and Kingella species) account for more than 90% of
endocarditis cases that may have a nosocomial or odontogenic
origin (Table 1; Murdoch et al., 2009; Raza et al., 2010; Ashrafi
et al., 2012; Selton-Suty et al., 2012). However, highest mortalities
occur with S. aureus and the non-HACEK group pathogens such
as Candida albicans (Ashrafi et al., 2012). Additionally, infective
endocarditis also can occur in intravenous drug abusers or in
association with HIV infection, diabetes mellitus, rheumatoid
arthritis, Sjögrens syndrome and cancer (Miro et al., 2002;
Filizcan et al., 2004; Sughimoto et al., 2006; Yoshioka et al., 2018;
Sanaiha et al., 2019; Table 1). These observations suggest that
multiple pathomechanisms may contribute to the development
of endocarditis.
Damage to the endocardium can result from valve sclerosis,
rheumatic valvulitis, or direct colonization/vegetation by bacteria
like S. aureus and Streptococcus species (Cahill and Prendergast,
2016). The main sequelae of endocarditis include damage to
the heart valve and endothelial scarring, leading to congestive
heart failure as might occur in autoimmune rheumatic diseases.
Endocarditis resulting from Streptococcus species., has been
used as a prototypic disease model to address how cross-
reactive autoimmune responses can lead to heart dysfunction
(Krisher and Cunningham, 1985; Cunningham et al., 1986).
It has been shown that mAbs specific to Streptococcus M
protein or the group A streptococcal epitope N-acetyl-βD-
glucosamine can cross-react with cardiac myosin and laminin
(Krisher and Cunningham, 1985; Galvin et al., 2000). The
finding that anti-streptococcal antibodies cross-react with human
and canine cardiac sarcolemma proteins but not kidney or
skeletal muscle, suggests that sarcoplasmic antigens can be
targeted in autoimmune endocarditis (Dale and Beachey, 1982;
Cunningham et al., 1986).
Animal models have been developed to study the immune
pathology of endocarditis and valvular inflammation.
Intraperitoneal injection of cell lysate from group A streptococci
into Swiss Webster mice results in aortic and mitral valve
stenosis, chronic inflammation, and scarring that mimic
human chronic rheumatic carditis (Cromartile and Craddock,
1966; Cunningham et al., 1984). In the Lewis rat model,
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immunization with streptococcal M protein leads to the
induction of cross-reactive T cells that are pathogenic in nature
(Quinn et al., 2001). Similarly, Lewis rats immunized with M
protein can develop valvulitis in mitral valves, but with minimal
myocardial involvement (Quinn et al., 2001). Expectedly,
lymph node cells obtained from immunized animals respond
to human cardiac myosin, but not human and rabbit skeletal
myosin and actin, although both human cardiac and skeletal
myosin share extensive sequence identity (Quinn et al., 2001).
However, it is interesting that, in spite of protein sequence
identity between streptococcal M proteins and cardiac myosin,
myocardial involvement was noted to be minimal relative
to valvulitis in the immunized Lewis rats. Likewise, laminin
present in the valves has been shown to cross-react with both
anti-streptococcal and myosin antibodies, and cross-reactive
T cells generated by immunization with laminin can induce
valvulitis without significant involvement of the myocardium
(Quinn et al., 2001).
Endocarditis can be seen in patients with RA, SLE, and
rheumatic fever, in which both joint and cardiovascular systems
could be affected. RA patients can also carry cardiac-specific
antibodies (Breed and Binstadt, 2015). To study the immune-
pathogenic mechanism of inflammatory arthritis, the K/BxN
TCR transgenic mouse model has been developed (Monach
et al., 2008). The transgenic mice express TCR specific to
glucose-6-phosphate isomerase (GPI), which plays a key role
in catalyzing the interconversion of glucose-6-phosphate to
fructose-6-phosphate (Chang and Wei, 2011). GPI-primed B
cells produce autoantibodies that can induce arthritis (Monach
et al., 2007). Recent studies suggest that transgenic mice
can develop both arthritis and endocarditis, but through two
independent pathways. While complement C5 protein is critical
for development of arthritis, but not endocarditis, occurrence
of endocarditis, but not arthritis, requires the participation of
FcRγ (Binstadt et al., 2009). Adoptive transfer of serum from
transgenic mice into naïve animals led to the development of
arthritis that was devoid of endocarditis, implying that arthritis is
an antibody-mediated disease (Maccioni et al., 2002). Conversely,
animals depleted of CD4+ T cells fail to develop endocarditis, but
arthritis remains unaffected, suggesting that T cells play a critical
role in the development of endocarditis (Binstadt et al., 2009).
Such disease models may be helpful in studying the immune
mechanisms of rheumatic diseases that involve both synovial
joints and/or the endocardium.
DISCUSSION
As described above, etiologically, IHD can be triggered by a
wide range of microbes, therefore posing a clinical challenge, that
necessitates identification of triggers to initiate pathogen-specific
therapies. Such avenues are clinically complicated, since affected
patients can have co-infections caused by microbes belonging
to different classes. For example, HIV patients can develop
pericarditis in association with S. aureus and M. tb infections
(Lamas et al., 2019). Similarly, myocarditis can result from co-
infection with HHV-6 and parvovirus B19 (Rohayem et al., 2001).
Likewise, some infections like EBV and parvovirus B19, may
occur as a result of their reactivation, respectively, in CVB3 and
hepatitis virus, and HHV-6 infections (Bock et al., 2014; Atti
et al., 2017). Such scenarios are likely because up to 95% of the
United States population is affected with EBV infection (Atti
et al., 2017). Furthermore, tissue destruction may not necessarily
result directly from cardiotropic pathogens like CVB3 and
adenovirus. For example, parvovirus B19 targeting endothelial
cells can induce myocarditis via endothelial dysfunction and
initiate inflammation (Bock et al., 2010).
Nevetheless, following infection-tiggered IHD, the immune
system in immune-competent individuals is expected to repair
the damaged tissue with or without successful clearance of
primary offenders. But such an ability of the immune system
to self-cure is relatively limited for cardiac cells, especially adult
cardiac myocytes because of their limited regenerative capacity
(Kikuchi and Poss, 2012). This scenario can be complicated by
the potential occurrence of secondary damage resulting from
autoimmune responses in genetically susceptible individuals. In
addressing this phenomenon, we have noted that CVB3 infection
can lead to the generation of cardiac myosin-specific T cells that
can contribute to post-infectious myocarditis in the absence of
detectable virions in infected animals (Gangaplara et al., 2012).
Based on this observation, we envision that cardiac-reactive
T cells specific for multiple autoantigens could be generated
in infections caused by cardiotropic pathogens that may have
implications in diagnosis and therapy of IHD.
Diagnostically, it is extremely challenging to identify
the causative agents for IHD with certainty, especially if
polymicrobes (co-infections) are involved. Additionally, one
or more manifestions of IHD (pericarditis, myocarditis, or
endocarditis) can potentially occur concurrently in affected
patients. Nonetheless, it may be possible to develop diagnostic
panels for commonly found pathogens like viruses and bacteria.
These may include PCR-based molecular markers or antibody
assays with the challenge that clinical specimens, especially
endomycardial biopsies, need to be collected in a timely fashion
to make a reliable diagnosis. This is especially important in
chronically affected individuals with no overt clinical signs
suggestive of known microbial infections. Such an approach, if
supported by routinely used serum biomarkers namely, cardiac
troponin I and T, creatinine kinase-MB, C-reactive protein,
myoglobin, natriuetic peptides, and sST2 (Biomarkers, 2014;
Nishimura et al., 2018; Coronado et al., 2019; Kottwitz et al.,
2020) may have diagnostic value. A limitation of this approach
is that the offending agents would be gone by that time, except
being suspects, which may not alter treatment approaches to be
followed clinically.
Thus, the complex nature of IHD is therapeutically
challenging in the medical management of affected individuals.
Although, various clinical trials reported thus far have yielded
mixed successes, two major approaches seem to be encouraging.
These include immune therapies (administration of intravenous
immunoglobulins or immunoglobulin adsorption), and anti-viral
agents. The former approach appeared to be effective in patients
with giant cell myocarditis and sarcoidosis who are negative for
viruses (Pollack et al., 2015). Conversely, this approach offered
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no advantage in those positive for viruses (Pollack et al., 2015).
The latter group of patients, however, can potentially be treated
with anti-viral agents as reported in parvovirus B19 (peramivir)
and influenza (acyclovir) infections, with or without immune
suppressive therapy, respectively (Dennert et al., 2010b; Baik
et al., 2015). Although such outcomes are rarely reported, the
therapeutic value of anti-viral compounds can be validated
only in large clinical trials that involve careful recruitment
of patient populations and appropriate controls. Finally, as to
autoimmunity, use of general immune suppressants potentially
elimimate most naïve lymphocytes that can seriously impair
a host’s defense mechanisms against microbes. Thus, immune
strategies are expected to target disease-inducing, autoreactive T
cells or B cells by sparing naïve repertoires. To this end, various
selective immune suppressants have been investigated that may
hold promise in the future.
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